Search News Archives
VIEW THE LATEST ISSUE
Microscopy | Image Analysis
IT Solutions and Laboratory Automation
Conferences | Events
Tecan offers increased sensitivity for qPCR of low input and degraded samples
Tecan has launched the Crescendo cDNA™ Synthesis for qPCR system to provide increased sensitivity for low input applications.
Developed specifically to meet the needs of researchers working with scarce, precious or degraded RNA samples – such as nasal swabs –it uses Tecan’s proprietary Single Primer Isothermal Amplification (SPIA®) technology to generate large quantities of cDNA from as little as 500 pg of total RNA.
Tecan’s robust, easy-to-use SPIA technology has a proven track record for use in qPCR applications, offering unbiased cDNA amplification across a broad input range. The newly created Crescendo kit optimizes this technique for limited, degraded or FFPE samples, allowing analysis of previously inaccessible samples and providing sufficient material for both qPCR and archiving. It offers a practical alternative to first strand synthesis for whole transcriptome approaches, dramatically increasing the number of copies of the target gene to enable accurate detection by qPCR. The kit is ideally suited to use with nasal swab and biopsy formats, allowing 500 pg to 50 ng of total RNA to be reliably amplified to generate micrograms of cDNA for downstream applications.
Rasmus Lind, General Manager at Tecan Genomics, commented: “The Crescendo cDNA Synthesis for qPCR system offers a flexible solution for labs performing whole transcriptome qPCR approaches. It provides significant amplification of samples across a broad input range, and represents a simple solution for sensitive qPCR and archiving, without consuming large amounts of precious samples.”
Learn more about Crescendo cDNA™
Tecan is a leading global provider of laboratory instruments and solutions in biopharmaceuticals, forensics and clinical diagnostics. The company specializes in the development, production and distribution of automated workflow solutions for laboratories in the life sciences sector. Its clients include pharmaceutical and biotechnology companies, university research departments, forensic and diagnostic laboratories. As an original equipment manufacturer (OEM), Tecan is also a leader in developing and manufacturing OEM instruments and components that are then distributed by partner companies. Founded in Switzerland in 1980, the company hasmanufacturing, research and development sites in both Europe and North America and maintains a sales and service network in 52 countries. In 2019, Tecan generated sales of CHF 637 million (USD 643 million; EUR 574 million). Registered shares of Tecan Group are traded on the SIX Swiss Exchange (TECN; ISIN CH0012100191).